Practice Areas

Home Practice Areas Pharmaceuticals & Biotechnology

Pharmaceuticals & Biotechnology

Recent work includes advising:

  • Amgen on its proposed acquisition of Horizon Therapeutics plc for an enterprise value of $28.3 billion.
  • Eli Lilly in proceedings seeking revocation of a Novartis patent and in the defence of infringement proceedings (including a competition law counterclaim against Novartis) with respect to Lilly’s product, Taltz®/ixekizumab for the treatment of psoriasis.
  • ViiV Healthcare in patent infringement proceedings against Gilead Sciences in respect of an anti-retroviral HIV treatment (Biktarvy®/Bictegravir) and in the defence of Gilead’s counterclaim for invalidity.
  • AstraZeneca in its appeal of the Controller of Intellectual Property’s decision not to grant an application for a SPC.
  • Genentech in its Commercial Court SPC patent infringement proceedings against Amgen in respect of an anti-VEGF antibody used in the treatment of cancer.
  • GlaxoSmithKline (GSK) in Commercial Court patent infringement proceedings against Pfizer and in defence of Pfizer’s counterclaim for invalidity. This case related to GSK’s MenB vaccine, BEXERO.
  • Boehringer Ingelheim in its defence of two sets of Commercial Court proceedings brought by Teva Pharmaceuticals seeking the revocation of a Boehringer Ingelheim patent and an SPC relating to Boehringer Ingelheim’s bestselling respiratory pharmaceutical product, SPIRIVA.
  • MSD Corp in the defence of Irish Commercial Court patent infringement proceedings brought by Bristol-Myers Squibb/Ono Pharmaceuticals / Tasuko Honjo relating to anti-PD-1 antibodies in the treatment of cancer and MSD’s product, KEYTRUDA.
  • GSK in its trade mark and passing off action against Rowex Limited and related companies involving the Seretide Inhaler, one of the all-time best-selling prescription drugs.
  • AbbVie / Allergan Acquisition on applicable provisions of the Irish Takeover Rules, and other relevant corporate and takeover law, to a significant shareholder of Allergan plc, in the context of AbbVie’s c.$60bn takeover of Allergan by scheme of arrangement under Ireland’s Companies Act 2014.
  • Research & Development
  • Clinical Trials
  • Regulatory Approval & Oversight
  • Commercialisation & Licensing
  • Manufacturing, Supply Chain & Distribution
  • Freedom to Operate
  • IP (contentious and non-contentious, including patent litigation)
  • Product Regulation & Liability
  • Professional Negligence
  • Data Protection & Privacy
  • Cyber Security